SCHEMBL4963197

SCHEMBL4963197

CCOC(=O)c1ncn(-c2ccccc2)c1C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.58
ALOX12 P18054 1/20 0.58
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57
GABRA2 P47869 5/20 0.56
GABRB2 P47870 4/20 0.56
ALDH1A1 P00352 4/20 0.54
GAA P10253 1/20 0.54
MAPT P10636 1/20 0.54
PDE4D Q08499 2/20 0.51
KDM4E B2RXH2 2/20 0.51
HPGD P15428 1/20 0.51
HSD17B10 Q99714 1/20 0.51
GABRG2 P18507 3/20 0.49
GABRB3 P28472 3/20 0.49
GABRA5 P31644 3/20 0.49
GABRA1 P14867 1/20 0.49
GABRA3 P34903 1/20 0.49
CNR2 P34972 1/20 0.47
PDE4A P27815 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21978539 0.88 ESR2 (0.50) TP53ALOX12NPC1RAB9AGABRA2
SCHEMBL69665 0.87 ALDH1A1 (0.56) TP53ALOX12NPC1RAB9AGABRA2
SCHEMBL21978369 0.86 L3MBTL1 (0.50) TP53ALOX12NPC1RAB9AGABRA2
SCHEMBL2113181 0.86 GABRA5 (0.49) TP53ALOX12NPC1RAB9AGABRA2
SCHEMBL21979193 0.86 PDE4D (0.53) TP53ALOX12NPC1RAB9AGABRA2
SCHEMBL1753102 0.86 ALDH1A1 (0.55) TP53ALOX12NPC1RAB9AGABRA2
SCHEMBL30707519 0.82 GABRA2 (0.50) TP53ALOX12NPC1RAB9AGABRA2
SCHEMBL23458339 0.82 NPC1 (0.44) TP53ALOX12NPC1RAB9AGABRA2
SCHEMBL29768506 0.82 NPC1 (0.44) TP53ALOX12NPC1RAB9AGABRA2
SCHEMBL21978654 0.81 MAPT (0.63) NPC1RAB9AALDH1A1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4540238-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME Monte Rosa Therapeutics AG (CH) 2025-04-23 EP disclosed
US-20250115582-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS AG (CH) 2025-04-10 US disclosed
WO-2023244818-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS, INC. (US) 2023-12-21 WO disclosed
US-8937184-B2 1H-imidazole derivatives as cannabinoid CB2 receptor modulators ABBVIE B.V. (NL) 2015-01-20 US disclosed
WO-2014160668-A1 TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-10-02 WO disclosed
EP-1874734-A1 1H-IMIDIAZOLE DERIVATIVES AS CANNABINOID CB2 RECEPTOR MODULATORS Solvay Pharmaceuticals B.V. (NL) 2008-01-09 EP disclosed
US-20060194779-A1 1H-imidazole derivatives as cannabinoid CB2 receptor modulators ABBVIE B.V. (NL) 2006-08-31 US disclosed
WO-2006087355-A1 1H-IMIDIAZOLE DERIVATIVES AS CANNABINOID CB2 RECEPTOR MODULATORS SOLVAY PHARMACEUTICALS B.V. (NL) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194779-A1 1H-imidazole derivatives as cannabinoid CB2 receptor modulators CNR1, CNR2, HRH4 TP53 4651/4885ALOX12 3148/4885NPC1 926/4885
US-20250115582-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME PSMA1, CSNK1G1, CSNK1A1 TP53 404/4885ALOX12 3329/4885NPC1 3893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.